TrialThe Lancet. Oncology2020

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.

Kara L Davis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.